EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Fibroblast activation protein and disease severity, progression, and survival in idiopathic pulmonary fibrosis

Thomas Skovhus Prior iD, Nils Hoyer iD, Jesper Rømhild Davidsen iD, Saher Burhan Shaker, Malthe Pallesgaard Hundahl iD, Søren Lomholt iD, Bent Winding Deleuran iD, Elisabeth Bendstrup iD, Tue Wenzel Kragstrup iD

Scandinavian Journal of Immunology · 2024-09 · 100 (3)

DOI: 10.1111/sji.13392 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Scandinavian Journal of Immunology, online erschienen am 07.06.2024. Verfasst von Thomas Skovhus Prior und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Diseases and Allergy, Center for Rare Lung Diseases, Aarhus University Hospital, Aarhus N, Denmark. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Disease Progression, Biomarkers, Severity of Illness Index. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim, Aarhus Universitet, TrygFonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic pulmonary fibrosis (IPF) is characterized by progressive fibrosis in the lungs. Activated fibroblasts play a central role in fibrogenesis and express fibroblast activation protein α. A truncated, soluble form (sFAP) can be measured in blood and is a potential novel biomarker of disease activity. The aim was to study the association between sFAP and clinical, radiological, and histopathological measures of disease severity, progression, and survival in a prospective, multicentre, real‐world cohort of patients with IPF. Patients with IPF were recruited from the tertiary interstitial lung disease centres in Denmark and followed for up to 3 years. Baseline serum levels of sFAP were measured by ELISA in patients with IPF and compared to healthy controls. Pulmonary function tests, 6‐minute walk test and quality of life measures were performed at baseline and during follow‐up. The study included 149 patients with IPF. Median sFAP in IPF was 49.6 ng/mL (IQR: 43.1–61.6 ng/mL) and in healthy controls 73.8 ng/mL (IQR: 62.1–92.0 ng/mL). Continuous sFAP was not associated with disease severity, progression or survival ( p > 0.05). After dichotomization of sFAP below or above mean sFAP + 2 SD for healthy controls, higher levels of sFAP were associated with lower FVC % predicted during follow‐up ( p < 0.01). Higher than normal serum levels of sFAP were associated with longitudinal changes in FVC % predicted, but sFAP did not show clear associations with other baseline or longitudinal parameters. As such, sFAP has limited use as a biomarker of disease progression or survival in patients with IPF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisDisease ProgressionBiomarkersSeverity of Illness IndexHumansMaleFemaleAgedMiddle AgedProspective StudiesRespiratory Function TestsQuality of LifeDenmarkFollow-Up Studies

Stichwörter der Autor:innen

fibroblast activation proteinidiopathic pulmonary fibrosisprognosis

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Respiratory Diseases and Allergy, Center for Rare Lung Diseases, Aarhus University Hospital, Aarhus N, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Respiratory Medicine, Herlev and Gentofte University Hospital, Hellerup, Denmark.
  • Department of Respiratory Medicine, South Danish Center for Interstitial Lung Diseases (SCILS), Odense University Hospital, Odense, Denmark.
  • Department of Biomedicine, Aarhus University, Aarhus, Denmark.
  • Department of Rheumatology, Aarhus University Hospital, Aarhus N, Denmark.

ORCID-Profile: Thomas Skovhus Prior, Nils Hoyer, Jesper Rømhild Davidsen, Malthe Pallesgaard Hundahl, Søren Lomholt, Bent Winding Deleuran, Elisabeth Bendstrup, Tue Wenzel Kragstrup

Förderung

  • Boehringer Ingelheim
  • Aarhus Universitet
  • TrygFonden
  • Ellen and Knud Dalhoff Larsen's Fund
  • Health Research Fund of the Central Denmark Region
  • Danish Lung Association's Fund

Zitieren

APA

Prior, T. S., Hoyer, N., Davidsen, J. R., Shaker, S. B., Hundahl, M. P., Lomholt, S., Deleuran, B. W., Bendstrup, E., & Kragstrup, T. W. (2024). Fibroblast activation protein and disease severity, progression, and survival in idiopathic pulmonary fibrosis. Scandinavian Journal of Immunology, 100(3). https://doi.org/10.1111/sji.13392

Vancouver

Prior TS, Hoyer N, Davidsen JR, Shaker SB, Hundahl MP, Lomholt S, et al. Fibroblast activation protein and disease severity, progression, and survival in idiopathic pulmonary fibrosis. Scandinavian Journal of Immunology. 2024;100(3). doi:10.1111/sji.13392

BibTeX
@article{Prior2024,
  author = {Prior, Thomas Skovhus and Hoyer, Nils and Davidsen, Jesper Rømhild and Shaker, Saher Burhan and Hundahl, Malthe Pallesgaard and Lomholt, Søren and Deleuran, Bent Winding and Bendstrup, Elisabeth and Kragstrup, Tue Wenzel},
  title = {Fibroblast activation protein and disease severity, progression, and survival in idiopathic pulmonary fibrosis},
  journal = {Scandinavian Journal of Immunology},
  year = {2024},
  volume = {100},
  number = {3},
  doi = {10.1111/sji.13392}
}
Kostenlos starten →